Is the timing of the repurchase aligned with expected earnings releases or catalyst events that could amplify the stock’s momentum?

Timing and catalyst alignment

The September 3 announcement comes just weeks before TG Therapeutics’ next quarterly filing (the Q3 2025 results are typically due in early‑to‑mid‑October). By completing the August‑2024‑announced $100 MM repurchase and simultaneously authorising an additional $100 MM buy‑back, the company is deliberately positioning a “liquidity cushion” ahead of its earnings call. The finished repurchase at an average $28.55 /‑share establishes a tangible price floor and sends a strong confidence signal to the market, which can help lift the stock’s momentum when earnings are released—especially if the quarter includes any positive clinical‑trial updates or guidance upgrades.

Trading implications

* Short‑term: Anticipate buying pressure in the near term as the market digests the finished buy‑back and the near‑term earnings catalyst. If the price holds above the $28.55 average repurchase price, a break‑out to $30–$31 (the next technical resistance on the weekly chart) is plausible on upside‑biased earnings news.

* Entry: Look for a pull‑back to $27.80‑$28.30 (the recent swing‑low support) with tightening volume—this offers a lower‑‑risk position ahead of the earnings window.

* Risk management: Keep a stop just below the $27.50 level (the prior month’s low) to protect against a sudden “buy‑back‑completion” fallout if earnings miss expectations.

Bottom line: The repurchase timing is clearly synchronized with the upcoming earnings season and the fresh $100 MM buy‑back authorization, creating a catalytic environment that can amplify TG Therapeutics’ price momentum. Traders with a bullish bias can consider positioning on the pull‑back now, targeting a breakout on the earnings‑driven catalyst, while remaining mindful of the defined downside stops.